ReviewDiscover oncology2025
Lipid metabolism in colorectal cancer: dual roles and statin therapy.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integration of clinical and cellular lipidomics identifies a serum metabolite signature predictive of oxaliplatin resistance in colorectal cancer.Functional & integrative genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a prevalent global malignancy with increasing incidence. This review systematically explores the intricate and often paradoxical dual roles of lipid metabolism components-triglycerides, cholesterol, HDL-C, and LDL-C-in CRC development and progression. A key focus is on the therapeutic potential of statins, cornerstone lipid-lowering agents. We summarize evidence that statins may confer protection through multifaceted mechanisms: inhibiting HMG-CoA reductase, modulating inflammation and immune responses, and reprogramming the gut microbiome. However, we critically synthesize the significant controversy surrounding their efficacy, attributing discrepant findings to factors such as statin lipophilicity, treatment duration, and tumor anatomical subsite. Ultimately, this review highlights the complex interplay between lipids and CRC and underscores the need for stratified, personalized approaches in future research and potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.